Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP230046.RASPG516SDRGGslZp8AS9D8fCLD7YZC38zbd66taOK26A130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP230046.RASPG516SDRGGslZp8AS9D8fCLD7YZC38zbd66taOK26A130_assertion type Assertion NP230046.RASPG516SDRGGslZp8AS9D8fCLD7YZC38zbd66taOK26A130_head.
- NP230046.RASPG516SDRGGslZp8AS9D8fCLD7YZC38zbd66taOK26A130_assertion description "[A significant decrease of SOD (P < 0.05), GPX (P < 0.05) and nonsignificant decrease of CAT (P > 0.05), and TAS status (P > 0.05) were seen in T2DM patients with neuropathy compared to T2DM patients as well as controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP230046.RASPG516SDRGGslZp8AS9D8fCLD7YZC38zbd66taOK26A130_provenance.
- NP230046.RASPG516SDRGGslZp8AS9D8fCLD7YZC38zbd66taOK26A130_assertion evidence source_evidence_literature NP230046.RASPG516SDRGGslZp8AS9D8fCLD7YZC38zbd66taOK26A130_provenance.
- NP230046.RASPG516SDRGGslZp8AS9D8fCLD7YZC38zbd66taOK26A130_assertion SIO_000772 22718504 NP230046.RASPG516SDRGGslZp8AS9D8fCLD7YZC38zbd66taOK26A130_provenance.
- NP230046.RASPG516SDRGGslZp8AS9D8fCLD7YZC38zbd66taOK26A130_assertion wasDerivedFrom befree-20140225 NP230046.RASPG516SDRGGslZp8AS9D8fCLD7YZC38zbd66taOK26A130_provenance.
- NP230046.RASPG516SDRGGslZp8AS9D8fCLD7YZC38zbd66taOK26A130_assertion wasGeneratedBy ECO_0000203 NP230046.RASPG516SDRGGslZp8AS9D8fCLD7YZC38zbd66taOK26A130_provenance.